Inhibitory effects of zinc hyaluronate on synoviocyte growth and matrix metalloproteinase-9 activity

Sodium hyaluronate (Na-HA) is a therapeutic agent used for treating knee arthritis. However, it has been unsuccessfully used in the treatment of knee effusions. Joint effusion results from synovial activation and growth, leading to an increase in the production of matrix metalloproteinases (MMPs), e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of inflammation research 2009-11, Vol.2 (default), p.45-57
Main Author: Seiji Saito, Seij
Format: Article
Language:English
Subjects:
Apoptosis
Arthritis
MMP-9
rheumatoid arthritis
sodium hyaluronate
synoviocyte
zinc hyaluronate
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sodium hyaluronate (Na-HA) is a therapeutic agent used for treating knee arthritis. However, it has been unsuccessfully used in the treatment of knee effusions. Joint effusion results from synovial activation and growth, leading to an increase in the production of matrix metalloproteinases (MMPs), especially MMP-9. This study aimed to determine whether the newly developed zinc hyaluronate (Zn-HA) is more effective than Na-HA in inhibiting the growth of synoviocytes or production and activity of MMPs in rheumatoid synoviocytes. Our results showed that Zn-HA inhibited synoviocyte growth, MMP-9 protein production, and MMP-9 mRNA expression, whereas Na-HA exerted only a slight inhibitory effect on these parameters. Moreover, Zn-HA induced synoviocyte apoptosis, whereas Na-HA did not. These results suggest that Zn-HA retards synoviocyte growth by inducing apoptosis following a decrease in the production of MMP-9 and mRNA. Therefore, it is suggested that Zn-HA can suppress arthritis more efficiently than Na-HA.
ISSN:1178-7031
1178-7031
DOI:10.2147/JIR.S7397